University Hospital
Grenoble, 38000, France
NCT Number: NCT01010165
Septic arthritis is a frequent, potentially disabling and/or life-threatening disease. To diagnose a septic arthritis is a complex procedure, first because of numerous differential diagnoses (such as crystal arthritis), second because of poor sensitivity of initial gram staining (for example after untimely antibiotic therapy).
This protocol will use SELDI-TOF as a tool to analyse joint fluid of patients with various acute, polymorphonuclear-rich arthritis, as to determine specific and sensitive new biomarkers of a septic origin.
Such biomarkers will allow rapid diagnosis of septic arthritis in the first hours of admission.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Grenoble, 38000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
University Hospital, Grenoble
Other
Caractérisation de Nouveaux Biomarqueurs de l'Arthrite Septique Par Technique SELDI-TOF
Acronym: NOUBASST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03345186
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Basel, Canton of Basel-City, Switzerland
View Trial DetailsNCT04585113
Arthritis, Crystal Arthritis
Copenhagen, DK, Denmark
View Trial DetailsNCT07329556
Ankylosing Spondylitis, Ankylosis
View Trial DetailsNCT05657847
Arthritis, Arthritis, Psoriatic
Budapest, Hungary
View Trial Details